ABL1 and atherosclerosis: Prior clinical trials with the ACAT-1 inhibitor avasimibe to assess safety in atherosclerosis patients have demonstrated that this drug can be safely administered with minimal toxicity.[26] Our data suggest that avasimibe could specifically target cancer cells with minimal toxicity to blood cells lacking BCR-ABL.